# 10x Genomics, Inc. Class A Common Stock (TXG) — Stock CV

10x Genomics, Inc. is a $10.6B technology company. Revenue shrank 4.3% over the last year, and it currently loses money.

> 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems.

## Identity

- **Ticker**: TXG
- **Sector**: Technology
- **Industry**: Laboratory Analytical Instruments
- **Headquarters**: PLEASANTON, CA
- **Employees**: 1 178
- **Website**: https://www.10xgenomics.com
- **Market cap**: $10.6B
- **Last price**: $81.05
- **Financial profile**: Strained

## Vitals (TTM)

- **Revenue**: $617M
- **Net income**: -$75.1M
- **Free cash flow**: $121M
- **Revenue growth (YoY)**: -4.3%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 30 |
| Growth | 12 |
| Profitability | 0 |
| Health | 25 |
| Quality | 35 |
| Moat | 25 |

## Qualifications (beginner checklist) — 4 of 9 passed

- [ ] Revenue growing — -4.3% YoY
- [ ] Profitable — -$75.1M TTM
- [x] Profit growing — +76.2% YoY
- [x] Generates cash — $121M TTM
- [x] Debt under control — current ratio 5.69
- [x] Established company — $10.6B market cap
- [ ] Not printing shares — +13.1% shares over ~5y
- [ ] Proven track record — 0/7 profitable years
- [ ] Financially stable — health score 25/100

## Experience (career milestones)

- **Sep 12, 2019** — 10x Genomics announced its initial public offering on September 12, 2019, raising $390M
- **2018** — The company announced its first acquisition, Epinomics, a biotechnology company focused on the…
- **2012** — 10x Genomics was founded in 2012 by Serge Saxonov, Ben Hindson and Kevin Ness to create advanced testing equipment…

## Strengths

- High gross margin (69.6%)
- Strong cash conversion — FCF is 19.7% of revenue

## Watch-outs

- Revenue shrinking 4.3% year over year
- Not profitable — 12.2% net margin
- Thin interest coverage (-75.7×)
- Loss-making in 7 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $490M | -$58.2M | -$123M |
| FY2022 | $516M | -$166M | -$165M |
| FY2023 | $619M | -$255M | -$63.8M |
| FY2024 | $611M | -$183M | -$5.73M |
| FY2025 | $643M | -$43.5M | $130M |

---

Source: https://stockcv.com/TXG — derived from company filings; may be delayed or incomplete. Information, not investment advice.